)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
AEON Biopharma (AEON) investor relations material
AEON Biopharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focus shifted to developing ABP-450 as a biosimilar to Botox for therapeutic indications after discontinuing Phase 2 migraine trials due to lack of efficacy and to preserve cash.
Positive biosimilarity data for ABP-450 confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX, supporting the biosimilar strategy and global market positioning.
FDA Type 2a meeting is scheduled for November 19, 2025, to review analytical study results and development plan.
Management transition occurred in April 2025, with Robert Bancroft appointed as CEO.
Two strategic financing transactions—a $6 million PIPE and a Daewoong note exchange—are expected to reduce outstanding debt by over 90%, strengthen the balance sheet, and extend the cash runway into Q2 2026.
Financial highlights
Net loss for Q3 2025 was $4.5 million, and for the nine months ended September 30, 2025, net loss was $2.1 million, compared to net income of $39.9 million for the same period in 2024 (driven by non-recurring items).
Cash and cash equivalents were $5.9 million as of September 30, 2025, excluding proceeds from the November PIPE financing.
Total current assets increased to $7.4 million as of September 30, 2025, from $1.6 million at December 31, 2024.
SG&A expenses decreased 36% year-over-year for Q3 2025, and R&D expenses decreased 40% for the same period, reflecting cost-cutting and program wind-downs.
Significant non-cash items included a $75.6 million loss on warrant issuance and $86.0 million income from change in fair value of warrants in 2025.
Outlook and guidance
Cash position, including recent financing, is expected to fund operations through the second quarter of 2026.
Additional funding will be required for further development of ABP-450 and to maintain operations beyond Q2 2026.
Management has concluded there is substantial doubt about the ability to continue as a going concern without new capital.
Upcoming FDA Type 2a meeting on November 19, 2025, will determine the path forward for ABP-450 biosimilar development.
What specific next steps follow Type 2a meeting?
What burn rate assumptions underpin Q2 2026 runway?
How does biosimilarity data support full-label access?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AEON Biopharma earnings date
Q4 202527 Mar, 2026
Next AEON Biopharma earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AEON Biopharma Inc. is a biopharmaceutical company focused on the development of therapeutic applications for botulinum toxin. The company aims to advance treatments for a range of medical conditions, particularly in neurology and related therapeutic areas. AEON Biopharma is engaged in clinical research and regulatory processes to expand the use of botulinum toxin beyond aesthetic applications. The company is headquartered in Irvine, California, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage